Generic products to be the growthfactor for bleeding disorders treatment market
The BleedingDisorder Treatment Market is driven by the large customer base, growingawareness about the bleeding disorders and available cures, and favorablecompensation policies. Patent expiry of existing brands will also providegeneric drug manufacturers opportunities to enter the lucrative bleedingdisorder therapeutics market. Market for bleeding disorder treatment is mostlyfocused towards western countries of North America and Europe, owing to thehigh price of branded drugs. Low cost drugs will help in market penetration inunder developed and developing countries, where patients cannot afford highcost of medical treatment. Hence,availability of cheap generic drugs will boost market growth in the countriesof Middle East and Africa, Asia-Pacific (APAC), and Latin America.
North America is estimated tocontribute the largest share of the market throughout the forecast period. Themarket in APAC is estimated to register the highest growth during the forecastperiod, owing to increasing awareness of these disorders in the emergingeconomies such as India and China.
The global bleeding disordertreatment market is highly competitive in nature. Technological advances willexpand the boundaries of the market by adding new products such as Shire launched Vonvendi in the U.S. (In 2016),bringing the first recombinant von Willebrand factor treatment to market eightmonths after winning approval from the Food and Drug Administration(FDA). Keyplayers operating in the global bleeding disorders treatment market are BayerHealthcare, Biogen Idec, Novo Nordisk, Xenetic Biosciences, Shire, Sanofi,Cangene Corporation, CSL Behring, Alnylam Pharmaceuticals, Pfizer, Inc., NovoNordisk, Amgen, Inc., Janssen Pharmaceuticals, and Octapharma.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/527
A bleeding disorder is a state inwhich the normal clotting function of blood is adversely affected. On an injuryto the body, blood normally starts to clot to prevent major loss of blood.Occasionally, certain situations prevent blood from clotting properly, whichcan result in heavy or prolonged bleeding. Bleeding disorders can causeabnormal bleeding both outside and inside of the body. Some disorders candrastically increase the amount of blood lost by the body. Others causebleeding to follow under the skin or in vigorous organs, such as the brain.Normal blood clotting involves blood components called ‘platelets’ and as manyas there are 20 different plasma proteins in body called as blood clotting orcoagulation factors. These factors interact with other chemicals to form asubstance called fibrin which stops bleeding. Complications can occur whencertain factors are low or missing in body. Bleeding problems can range frommild to severe. Some bleeding disorders are present at time of birth and someare passed through families (inherited).
According to American Society ofHematology, in 2016, around 20,000 people in the U.S. suffer from hemophilia, acondition that is predominantly observed in males. Hemophilia is the most well-known inheritedbleeding disorder, although it is rather rare. On the other hand, many peopleare affected by von Willebrand disease, the most common inherited bleedingdisorder in the U.S. caused by clotting proteins. This disease can affect bothmales and females and is found in nearly 1% of the U.S. population. Andaccording to the Centers for Disease Control and Prevention (CDC) statistics,in the U.S. around 400 newborns suffer from hemophilia every year.
Key Developments:
In February 2020, Novo NordiskA/S launched Esperoct, an anti-hemophilic factor in U.S. for the treatment ofadults and children with hemophilia A i.e., to reduce as well as control thebleeding episodes even during surgery.
In December 2019, Johnson andJohnson in collaboration with Spanish multinational, Grifols, producedVistaseal biological sealant, which is a blood stopping protein spray and isdesigned to quickly seal and control bleeding during complicated surgerieswhere suturing, ligature or cauterization cannot be applied. The spray consistof two clotting, human fibrinogen and thrombin, which helps in the sealing ofthe wound.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/bleeding-disorders-treatment-market-527
In 2018, on the occasion of 70thanniversary of National Hemophilia Foundation (NHF), a Red Tie Campaign waslaunched in order to create awareness about the bleeding disorders. The mainaim of the campaign was to increase the accessibility of the quality healthcareto the patient suffering from bleeding disorders by providing them healthinsurance with life time benefits.
In 2018, European Association forHemophilia and Allied Disorders formed a working group on women and bleedingdisorders after receiving the approval for the proposal. The aim of the workinggroup is to educate the healthcare providers and understand the needs of thewomen with bleeding disorders.
In 2017, LFB Biopharmaceuticalslaunched FibCLOT, the human fibrinogen concentrate. FibCLOT is effective inpatients with congenital hypo- or afibrinogenaemia and who have high tendencyto bleed.
In 2017, Pfizer launchedHemocraft, a modification of the video game Minecraft, especially for childrenwho are 8-16 years old. The game educates the children about the importance ofintegrating treatment in their daily lives.
In 2017, another modification byPfizer involves the development of HemMobile Striiv Wearable wrist band, forthe patients suffering from hemophilia. The device helps to track dailyactivity levels and also monitors heart rate. The device integrates with thePfizer’s existing HemMobile app, which helps people to monitor their bleedingepisodes.
In June 2016, a scientist workingat Kingston Health Sciences Center (KGHRI) launched a website “Let’s TalkPeriod”, where the women need fill the “self- administered bleeding assessment”(Self – BAT) form in order to diagnose whether they are suffering from bleedingdisorders or not. The website also directs the women to the referral centerswhere they can consult with the respective doctors for the effective treatment.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/527
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
